Drug intelligence / Profile preview

AI-168

Development stage: Preclinical
Lead developer: Algorae Pharmaceuticals
Modality: Small Molecules

Overview

**AI-168** is an Algorae preclinical fixed-dose cardiovascular drug candidate discovered using the AlgoraeOS platform. It combines cannabidiol with an off-patent cardioselective beta blocker, although Algorae has not publicly identified the precise beta-blocker component. The program is intended for cardiovascular disease including hypertension, with preclinical studies reporting restoration of endothelial and smooth-muscle cell phenotypes and reduced cardiomyocyte damage in cellular models. AI-168 is covered by international patent application PCT/AU2024/051253. ([algoraepharma.com](https://algoraepharma.com/algoraeos/cardiovascular/))

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on AI-168.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI-168.

Explore the full profile